PD‐L1 and HLA‐I expression was assessed on CTCs as potential pharmacodynamic biomarkers of ICIs and TKIs that may also reflect phenotypic heterogeneity in ccRCC. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.